title: Prevention of pterygium recurrence by postoperative single-dose beta-irradiation: a prospective randomized clinical double-blind trial.
abstract: OBJECTIVE
  To affirm the effectiveness and complication rate of postoperative single-dose beta-irradiation (RT) with (90)Sr in the case of primary pterygium in a clinical trial. Pterygium is a benign disease of the supporting orbital tissue that can cause impairment of visual function. Depending on the technique used for surgery, recurrence is described in up to 70% of cases-a reason to combine the initial treatment with radiotherapy or chemotherapy.
  
  
  METHODS
  This trial was designed as a prospective, randomized, multicenter, double-blind study. Surgery was performed in all cases according to the bare sclera technique. Ninety-one patients with 96 pterygia were postoperatively randomized to either beta-RT or sham RT. In the case of beta-RT, a (90)Sr eye applicator was used to deliver 2500 cGy to the sclera surface at a dose rate of between 200 and 250 cGy/min. Sham RT was given using the same type of applicator without the (90)Sr layer. After treatment, both an ophthalmologist and a radiation oncologist performed the follow-up examinations. The accumulated data were analyzed using a group sequential test.
  
  
  RESULTS
  Between February 1998 and September 2002, 96 eyes with primary pterygium were operated on according to the trial protocol. Additional treatment was performed within 24 hours postoperatively. Ten patients were lost to follow-up, resulting in 86 patients who could be analyzed. In the 44 eyes randomized to receive beta-RT, 3 relapses occurred compared with 28 recurrences in the 42 eyes that received sham RT, for a crude control rate of 93.2% vs. 33.3%, respectively. At a mean follow-up of 18 months, major treatment complications had not been observed.
  
  
  CONCLUSIONS
  Single-dose beta-RT after bare sclera surgery is a simple, effective, and safe treatment that reduces the risk of primary pterygium recurrence.
authors.affiliation: Department of Radiation Oncology, University Medical Centre Utrecht, Heidelberglaan 100, NL-3584 CX Utrecht, The Netherlands. i.m.Schultz@azu.nl
authors.forename: Ina M
authors.initials: IM
authors.lastname: Jürgenliemk-Schulz
authors.forename: Lidy J C
authors.initials: LJ
authors.lastname: Hartman
authors.forename: Judith M
authors.initials: JM
authors.lastname: Roesink
authors.forename: Robbert J H A
authors.initials: RJ
authors.lastname: Tersteeg
authors.forename: Ingeborg
authors.initials: I
authors.lastname: van Der Tweel
authors.forename: Henk B
authors.initials: HB
authors.lastname: Kal
authors.forename: Maarten P
authors.initials: MP
authors.lastname: Mourits
authors.forename: Harm K
authors.initials: HK
authors.lastname: Wyrdeman
mesh_terms: D000328:Adult; D000368:Aged; D003131:Combined Modality Therapy; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011625:Pterygium / Q000532:radiotherapy* / Q000601:surgery; D055502:Secondary Prevention; D013326:Strontium Radioisotopes / Q000627:therapeutic use*
chemical_list: D013326:Strontium Radioisotopes